Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T05904 Target Info
Target Name Phosphodiesterase 8 (PDE8)
Synonyms High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A
Target Type Patented-recorded Target
Gene Name PDE8A
Biochemical Class Phosphoric diester hydrolase
UniProt ID
PDE8A_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9493447
Title Optically active PDE10 inhibitor
Abstract The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.
Applicant(s) Omeros Corporation
Representative Drug(s) D0EN2M Drug Info IC50 > 10000nM [1]
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Representative Drug(s) D0SH7F Drug Info IC50 > 100000nM [2]
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Representative Drug(s) D0SH7F Drug Info IC50 > 100000nM [2]
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Representative Drug(s) D0SH7F Drug Info IC50 > 100000nM [2]
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Representative Drug(s) D0SH7F Drug Info IC50 > 100000nM [2]
Patent ID US8846654
Title Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
Abstract A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.
Applicant(s) Sanofi
Representative Drug(s) D05SRL Drug Info IC50 = 15 nM Click to Show More [3]
2 D0EF6R Drug Info IC50 = 140 nM [3]
3 D0A5JS Drug Info IC50 = 390 nM [3]
Patent ID US8846654
Title Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
Abstract A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.
Applicant(s) Sanofi
Representative Drug(s) D05SRL Drug Info IC50 = 15 nM Click to Show More [3]
2 D0EF6R Drug Info IC50 = 140 nM [3]
3 D0A5JS Drug Info IC50 = 390 nM [3]
Patent ID US8846654
Title Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
Abstract A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.
Applicant(s) Sanofi
Representative Drug(s) D05SRL Drug Info IC50 = 15 nM Click to Show More [3]
2 D0EF6R Drug Info IC50 = 140 nM [3]
3 D0A5JS Drug Info IC50 = 390 nM [3]
References  Top
REF 1 Optically active PDE10 inhibitor. US9493447.
REF 2 Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
REF 3 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.